# PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients

> **NCT04046484** · PHASE2 · COMPLETED · sponsor: **Pharmazz, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Acute Stroke
- Cerebral Ischemia

## Interventions

- **DRUG:** Normal Saline along with standard treatment
- **DRUG:** PMZ-1620 along with standard treatment

## Key facts

- **NCT ID:** NCT04046484
- **Lead sponsor:** Pharmazz, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-19
- **Primary completion:** 2019-04-12
- **Final completion:** 2019-06-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04046484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04046484, "PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04046484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*